Understanding the Human Histone Methyltransferase SMYD3
Author Information
Author(s): Kenneth W. Foreman, Mark Brown, Frances Park, Spencer Emtage, June Harriss, Chhaya Das, Li Zhu, Andy Crew, Lee Arnold, Salam Shaaban, Philip Tucker
Primary Institution: OSI Pharmaceuticals, Inc.
Hypothesis
What is the structural and functional role of the human histone methyltransferase SMYD3 in cancer progression?
Conclusion
The study reveals that SMYD3 has a unique structure that allows it to preferentially trimethylate histone H4 at lysine 20, which may play a role in cancer progression.
Supporting Evidence
- SMYD3 was shown to have a preference for trimethylation of histone H4 at lysine 20.
- The study provided a detailed structural basis for the enzymatic activity of SMYD3.
- Mutational analyses confirmed the regulatory roles of specific structural elements in SMYD3.
Takeaway
SMYD3 is a protein that helps control how genes are turned on or off by adding special tags to histones, which are like spools for DNA. This study shows how SMYD3 works and why it might be important in cancer.
Methodology
The researchers analyzed the crystal structure of SMYD3 and conducted mutational and biochemical assays to assess its enzymatic activity.
Limitations
The study does not fully elucidate the conformational changes required for substrate release.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website